Meeting
2016 Gastrointestinal Cancers Symposium
Phase II study of dovitinib in patients (Pts) progressing on anti-vascular endothelial growth factor (VEGF) therapy.
Authors
Thomas John Semrad
University of California, Davis, Sacramento, CA
Thomas John Semrad , Edward Jae-hoon Kim , Michael S. Tanaka , Jacob Sands , Chris Roberts , Stephanie H. Astrow , Craig Stephens , Miriana Moran , Rebekah Burich , Yu Li , David R. Gandara , Primo Lara Jr., Philip C. Mack
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Clinical Trial Registration Number
NCT01676714
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 616)
DOI
10.1200/jco.2016.34.4_suppl.616
Abstract #
616
Poster Bd #
F21
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
NIVACOR: Phase II study of nivolumab in combination with FOLFOXIRI/bevacizumab in first-line chemotherapy for advanced colorectal cancer RASm/BRAFm patients.
First Author: Angela Damato
Poster
2013 ASCO Annual Meeting
Phase II study of metronomic chemotherapy (MC) with bevacizumab (B) in patients (Pts) with advanced (Adv) nonsquamous non-small cell lung cancer (NS-NSCLC).
First Author: Carrie Lee Marquette
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug (casdozo, SRF388) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced, or metastatic hepatocellular carcinoma (uHCC).
First Author: Daneng Li
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Clinical development and evaluation of plasma angiogenesis factors from phase II study of FOLFIRI plus ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin/fluoropyrimidine (RAINCLOUD): RAINCLOUD-TR.
First Author: Tsuyoshi Hata